ConcertAI

Overview

ConcertAI is a Cambridge, Massachusetts-based oncology AI and real-world data (RWD) company providing Data-as-a-Service (DaaS) and AI Software-as-a-Service (SaaS) solutions to life sciences companies, healthcare providers, and medical societies. Founded in 2017-2018 as a spinout of SymphonyAI Group (now SAIGroup), the company is purpose-built around the hypothesis that AI applied to large-scale, curated oncology data can meaningfully compress the drug development timeline and improve clinical decisions.

ConcertAI is a portfolio company of SAIGroup, the private AI conglomerate founded by Dr. Romesh Wadhwani — a Silicon Valley serial entrepreneur who has committed up to $1 billion in personal capital to the portfolio. Wadhwani serves as Executive Chairman. This structure means ConcertAI is majority-controlled by a single founder-owner rather than venture funds, providing unusual strategic patience relative to VC-backed peers.

Leadership: Eron Kelly (CEO, appointed May 2025 — cloud-based healthcare SaaS background), Dr. Jeff Elton (Vice Chairman, founding CEO who led through $200M revenue), Dr. Claudio D’Ambrosio (Chief Science Officer).

Scale: 1,000+ employees. Offices in Cambridge, Philadelphia, Raleigh-Durham, Bangalore, Frankfurt, Tokyo. Serves 75% of top 30 life sciences companies and 50+ biopharma innovators. 2,000+ healthcare providers and research sites globally. 9M+ de-identified cancer patient records across all 50 U.S. states.

Services & Capabilities

ConcertAI operates across three interlocking service layers: data assets, AI software, and scientific/analytical services.

1. Real-World Data (RWD) Assets

CancerLinQ — Acquired from ASCO in December 2023. 100+ cancer centers, 10 EMR integrations, ~7-9 million patient records. ConcertAI committed $250M+ to expand post-acquisition.

Patient360 — EHR-derived, regulatory- and registry-grade longitudinal patient records for evidence generation and RWE submissions.

CTO-H — Joint hematology dataset with NeoGenomics: 370,000+ patient lives with 7-11 years of surveillance — the largest hematology reference dataset in existence.

Clinico-Genomic Layer — Partnerships with Caris Life Sciences, Guardant Health, NeoGenomics, and Foundation Medicine (January 2026) create what ConcertAI claims is the largest clinico-genomic oncology dataset at nearly 500,000 linked patients. Multi-modal inputs: EMR, liquid biopsy, solid tumor genomics, digital pathology, and CT/MRI imaging (TeraRecon).

2. AI SaaS Platform (CARAai)

Introduced January 2024. Oncology-tuned LLMs, large reasoning models, and small language models combined with NVIDIA NIM microservices (Llama 3), predictive AI, and agentic AI capabilities.

Product	Function
Precision360	Population-scale GenAI/Agentic AI curated data solution (2025 launch)
Translational360	Integrated longitudinal clinical-molecular database for translational research
Accelerated Clinical Trials (ACT)	Agentic AI to shorten trial timelines by 10-20 months (Feb 2026 launch)
CTO	AI-driven trial design for solid tumor oncology
CTO-H	Hematology-specific trial design (with NeoGenomics)
Commercial Solutions SaaS	AI-managed service for biopharma commercial teams (80+ therapeutics)
SmartLinQ	Oncology practice quality reporting via CancerLinQ

3. How It Serves Pharma

Translational/early development: Multi-modal clinico-genomic data for target identification, biomarker hypothesis testing, basket trial design. The Bayer multi-year agreement (April 2025) uses Translational360 to prioritize development programs.

Clinical development: DACT platform and CARAai trial matching reduce recruitment cycles by identifying eligible patients across the CancerLinQ network.

Regulatory/RWE: Five-year FDA CDER collaborative research agreement (initiated June 2021) on RWD methods — meaningful regulatory legitimacy signal.

Commercialization: Commercial Solutions SaaS provides AI-derived insights on real-world drug utilization, patient journeys post-approval, and treatment sequencing.

4. TeraRecon (Imaging AI)

Acquired by SAIGroup in 2020, integrated into ConcertAI November 2021. Advanced radiology visualization and clinical AI decision support for MRI and CT. 1,300+ clinical sites globally. KLAS Category Leader for Advanced Visualization (2020-2022). Differentiates ConcertAI from purely EHR-based competitors by enabling true multi-modal data linkage.

Competitive Position

Competitor	Owner	Data Scale	Key Differentiator	Weakness vs. ConcertAI
Flatiron Health	Roche ($2.1B, 2018)	5M+ patient journeys, 22+ tumor types	Deepest curated oncology EHR data	Roche ownership creates conflict-of-interest for non-Roche pharma
IQVIA	Public (IQV)	100M+ records across modalities	Breadth, global reach	Not oncology-specialized; weaker genomic linkage
Tempus	Public (TEM, IPO June 2024)	7M+ patients sequenced	Genomics-first; diagnostics funds data flywheel	Data & Services revenue smaller; still EBITDA-negative
Komodo Health	Private (SoftBank)	330M+ longitudinal journeys	Breadth of patient universe	Not oncology-specialized; claims-only

ConcertAI’s advantages: (1) Oncology-only specialization with multi-modal depth. (2) CancerLinQ acquisition closes key data gap — 100+ cancer centers feeding dataset. (3) Molecular data partnerships create largest clinico-genomic layer (~500K linked patients). (4) Imaging integration via TeraRecon — unique in the RWE space. (5) FDA CDER research collaboration provides regulatory credibility.

Weaknesses: Scale gap vs. Flatiron on data longevity. Tempus has diagnostics-funded self-reinforcing data flywheel. Private ownership limits market visibility.

Recent Developments

December 2023 — CancerLinQ Acquisition. Acquired ASCO’s CancerLinQ subsidiary. Committed $250M+ to expand.

January 2024 — CARAai Platform Launch (JPM). Publicly introduced the CARAai architecture.

June 2024 — NVIDIA Collaboration. NIM microservices integration for large-scale clinical simulations.

December 2024 / January 2025 — CTO-H Launch. Joint hematology SaaS with NeoGenomics. 370,000+ patients.

January 2025 — Guardant Health DaaS Partnership. First multi-modal RWD product integrating EMR with genomic and epigenomic profiling (including methylation data).

January 2025 — JPM Update. FY2024 revenues ~$200M; ~30% ARR growth; 72% ARR; profitable with mid-teens EBITDA margins.

April 2025 — Bayer Multi-Year Agreement. Translational360 and AI SaaS for precision oncology program prioritization.

May 2025 — CEO Transition. Eron Kelly appointed CEO; Jeff Elton to Vice Chairman. Signals shift from build to scale mode.

January 2026 — Foundation Medicine Clinico-Genomic Dataset. Strategic collaboration creating ~500,000 linked patients with FDA-approved diagnostic signatures, WSI, gene expression, and IHC results. Most significant data expansion since CancerLinQ.

February 2026 — Accelerated Clinical Trials (ACT) Launch. Agentic AI platform to shorten trial timelines by 10-20 months. Frost & Sullivan top AI Clinical Trial Automation Solution 2026.

Financial Profile

Metric	FY2023	FY2024
Revenue	~$160-200M	Targeting/achieving $200M+
ARR growth	~30%	—
ARR % of total revenue	75%	72% (highest ever)
EBITDA	Profitable	Profitable; mid-teens margins
Valuation (last round)	$1.9B (March 2022)	No new round

Funding: $150M Series B (Jan 2020, Declaration Partners/Maverick Ventures lead), $150M Series C (Mar 2022, Sixth Street lead). Total disclosed external: ~$300M. One source cited ~$600M total including SAIGroup internal investment (unconfirmed).

The $1.9B valuation is three years stale, set during peak healthcare tech multiples. 72% ARR penetration is a high-quality revenue profile. No new funding round since 2022 — either self-funding via SAIGroup or avoiding a new valuation test.

Sources

• ConcertAI JPM 2025, JPM 2024, Sixth Street Series C, The Cancer Letter CancerLinQ, NVIDIA collaboration, Foundation Medicine collaboration, Bayer agreement, CEO transition, TeraRecon integration, ACT launch
• Perplexity Wave 2 Agent 17 enrichment (raw/research/09_concertai.md)